IESS-I
Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study
N = 342
- Population
- Previously untreated eligible children with primary nonmetastatic Ewing's sarcoma of bone; 342 entered
- Design
- Randomised; group I institutions randomised patients between treatment 1 (radiotherapy to the primary lesion plus VAC, i.e. cyclophosphamide, vincristine, dactinomycin, plus doxorubicin) and treatment 2 (VAC without doxorubicin); group II institutions randomised between treatment 2 and treatment 3 (VAC plus bilateral pulmonary radiotherapy). 342 eligible previously untreated children entered between May 1973 and November 1978 according to the 1990 long-term follow-up report; the original 1981 report describes 264 randomised children and adults treated at 83 institutions of three study groups from 1973 to 1978 (the abstracts do not explain the difference).
- Arms
- Treatment 2: VAC (control): Radiotherapy to the primary lesion plus cyclophosphamide, vincristine and dactinomycin (VAC)
- Treatment 1: VAC plus doxorubicin (experimental): Radiotherapy to the primary lesion plus VAC and doxorubicin (ADR)
- Treatment 3: VAC plus bilateral pulmonary radiotherapy (experimental): Radiotherapy to the primary lesion plus VAC and bilateral pulmonary radiotherapy (BPR)
- People
- Nesbit ME Jr
Δ 60-month RFS+36 points
Show the numbers
| Endpoint | Analysis | Treatment 1: VAC plus doxorubicin / Treatment 3: VAC plus bilateral pulmonary radiotherapy | Treatment 2: VAC | Effect |
|---|---|---|---|---|
| RFSEligible patients entered on IESS-I (342) | long term-updateNesbit 1990 | 60% at 5 y | 24% at 5 y | P<.001 (treatment 1 vs 2); <.05 (1 vs 3); <.001 (3 vs 2)Percentage of patients relapse-free and surviving at 5 years. Randomisation pairs differed by institution group (1 vs 2, or 2 vs 3). |
| Endpoint | Analysis | Treatment 1: VAC plus doxorubicin / Treatment 3: VAC plus bilateral pulmonary radiotherapy | Treatment 2: VAC | Effect |
|---|---|---|---|---|
| RFSEligible patients entered on IESS-I (342) | long term-updateNesbit 1990 | 60% at 5 y | 24% at 5 y | P<.001 (treatment 1 vs 2); <.05 (1 vs 3); <.001 (3 vs 2)Percentage of patients relapse-free and surviving at 5 years. Randomisation pairs differed by institution group (1 vs 2, or 2 vs 3). |
Appears in
Sources
Nesbit ME Jr, Perez CA, Tefft M, Burgert EO Jr, Vietti TJ, Kissane J, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study. Natl Cancer Inst Monogr. 1981;(56):255-62.
Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990;8(10):1664-74.